Author:
Lai Yanni,Zhang Qiong,Long Haishan,Han Tiantian,Li Geng,Zhan Shaofeng,Li Yiwei,Li Zonghui,Jiang Yong,Liu Xiaohong
Abstract
Background: Ganghuo Kanggan decoction (GHKGD) is a clinical experience prescription used for the treatment of viral pneumonia in the Lingnan area of China, and its clinical effect is remarkable. However, the mechanism of GHKGD in influenza is still unclear.Objective: To predict the active components and signaling pathway of GHKGD and to explore its therapeutic mechanism in influenza and to verified it in vivo using network pharmacology.Methods: The potential active components and therapeutic targets of GHKGD in the treatment of influenza were hypothesized through a series of network pharmacological strategies, including compound screening, target prediction and pathway enrichment analysis. Based on the target network and enrichment results, a mouse model of influenza A virus (IAV) infection was established to evaluate the therapeutic effect of GHKGD on influenza and to verify the possible molecular mechanism predicted by network pharmacology.Results: A total of 116 candidate active compounds and 17 potential targets were identified. The results of the potential target enrichment analysis suggested GHKGD may involve the RLR signaling pathway to reduce inflammation in the lungs. In vivo experiments showed that GHKGD had a protective effect on pneumonia caused by IAV-infected mice. Compared with the untreated group, the weight loss in the GHKGD group in the BALB/c mice decreased, and the inflammatory pathological changes in lung tissue were reduced (p < 0.05). The expression of NP protein and the virus titers in lung were significantly decreased (p < 0.05). The protein expression of RIG-I, NF-kB, and STAT1 and the level of MAVS and IRF3/7 mRNA were remarkably inhibited in GHKGD group (p < 0.05). After the treatment with GHKGD, the level of Th1 cytokines (IFN-γ, TNF-α, IL-2) was increased, while the expression of Th2 (IL-5, IL4) cytokines was reduced (p < 0.05).Conclusion: Through a network pharmacology strategy and in vivo experiments, the multi-target and multi-component pharmacological characteristics of GHKGD in the treatment of influenza were revealed, and regulation of the RLR signaling pathway during the anti-influenza process was confirmed. This study provides a theoretical basis for the research and development of new drugs from GHKGD.
Funder
National Natural Science Foundation of China
Subject
Pharmacology (medical),Pharmacology
Reference42 articles.
1. Animal models for the study of influenza pathogenesis and therapy;Barnard;Antivir. Res.,2009
2. Todesfälle durch Influenzapandemien in Deutschland 1918 bis 2009. Schätzwerte auf Basis der Literatur und ergänzende eigene Berechnungen [Influenza pandemic deaths in Germany from 1918 to 2009. Estimates based on literature and own calculations];Buchholz;Bundesgesundheitsblatt—Gesundheitsforsch.—Gesundheitsschutz,2016
3. Effects of Ganghuo Kanggan Decoction on viral pneumonia mice caused by H1N1 influenza virus;Chen;CJTCMP,2015
4. Host immune response to influenza A virus infection;Chen;Front. Immunol.,2018
5. The 2009 pandemic in Mexico: experience and lessons regarding national preparedness policies for seasonal and epidemic influenza. La pandemia de 2009 en México: experiencia y lecciones acerca de las políticas nacionales de preparación contra la influenza estacional y epidémica;Cordova-Villalobos;Gac. Med. Mex.,2017
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献